INVESTABOT
Equity Research
XNYS · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-08-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one …
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-07-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 2 Form 144 pre-sale notices filed on 2026-07-30. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-07-27. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 2 Form 144 pre-sale notices filed on 2026-05-29. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-27. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-18. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one …
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one …
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-22. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Edwards Lifesciences reported Q1 2026 total sales of $1.65 billion, with its flagship TAVR segment growing 14.4% to $1.2 billion and EPS of $0.66 — strong enough that management raised full-year guidance immediate…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/11/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | -619 | — | — |
| 8/11/2026 | Lippis Daniel J. | CVP, TAVR | SELL | -619 | $92 | $56,967 |
| 8/11/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | 619 | $73 | $44,989 |
| 7/30/2026 | Markowitz Wayne | CVP, JAPAC | SELL | -146.31 | $86 | $12,588 |
| 7/28/2026 | Markowitz Wayne | CVP, JAPAC | OPTION_EXERCISE | 9,628 | $74 | $712,665 |
| 7/28/2026 | Markowitz Wayne | CVP, JAPAC | SELL | -9,628 | $85 | $818,958 |
| 7/28/2026 | Markowitz Wayne | CVP, JAPAC | OPTION_EXERCISE | -9,628 | — | — |
| 7/27/2026 | Zovighian Bernard J | CEO | GIFT | -319.65 | — | — |
| 7/27/2026 | Zovighian Bernard J | CEO | GIFT | 319.65 | — | — |
| 7/27/2026 | Zovighian Bernard J | CEO | SELL | -2,920.55 | $84 | $245,134 |
| 7/11/2026 | Bruls Annette | CVP, EMEACLA | TAX_WITHHOLD | -109 | $92 | $10,051 |
| 7/10/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | 619 | $73 | $44,989 |
| 7/10/2026 | Lippis Daniel J. | CVP, TAVR | SELL | -619 | $92 | $56,762 |
| 7/10/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | -619 | — | — |
| 7/9/2026 | Mistras Theodora | CVP, Chief Financial Officer | GRANT | 87,595 | — | — |
| 7/9/2026 | Mistras Theodora | CVP, Chief Financial Officer | GRANT | 12,325 | — | — |
| 7/9/2026 | Mistras Theodora | CVP, Chief Financial Officer | GRANT | 61,800 | — | — |
| 7/7/2026 | Lippis Daniel J. | CVP, TAVR | TAX_WITHHOLD | -377 | $95 | $35,883 |
| 6/30/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | 619 | $73 | $44,989 |
| 6/30/2026 | Lippis Daniel J. | CVP, TAVR | SELL | -619 | $91 | $56,577 |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 8/11/2026 | Lippis Daniel J. | — | 1,857 | SEC |
| 7/30/2026 | Markowitz Wayne | — | 147 | SEC |
| 7/30/2026 | Ullem Scott B. | — | 50,000 | SEC |
| 7/28/2026 | Markowitz Wayne | — | 9,628 | SEC |
| 7/27/2026 | Zovighian Bernard J | — | 2,921 | SEC |
| 5/29/2026 | Dahl Andrew M. | — | 568 | SEC |
| 5/29/2026 | Ullem Scott B. | — | 64,152 | SEC |
| 5/27/2026 | BOBO JR FAMILY TRUST | — | 23,145 | SEC |
| 5/22/2026 | Chopra Daveen | — | 1,500 | SEC |
| 5/18/2026 | Lippis Daniel J. | — | 1,858 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| 6/1/2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 70,079,435 | $5,974,271,834 | — | 1/29/2026 |
| BlackRock | 58,789,433 | $5,318,092,039 | 11.5% | 8/7/2026 |
| BlackRock | 50,975,492 | $4,708,606,210 | — | 8/13/2024 |
| BlackRock | 52,461,915 | $4,472,378,277 | — | 2/12/2026 |
| BlackRock | 52,728,933 | $4,222,532,929 | 0.5% | 5/13/2026 |
| State Street | 26,321,940 | $2,381,082,692 | 0.1% | 8/7/2026 |
| JP Morgan Chase | 26,349,452 | $2,246,290,811 | — | 2/11/2026 |
| State Street | 25,991,524 | $2,215,777,421 | — | 2/13/2026 |
| State Street | 26,296,399 | $2,105,815,632 | 1.2% | 5/15/2026 |
| JP Morgan Chase | 23,053,175 | $2,101,988,596 | 5.3% | 8/12/2026 |
| JP Morgan Chase | 21,889,712 | $1,740,232,166 | -16.9% | 5/13/2026 |
| Fidelity (FMR) | 16,582,547 | $1,413,662,134 | — | 2/17/2026 |
| Fidelity (FMR) | 14,503,770 | $1,161,461,852 | -12.5% | 5/15/2026 |
| Fidelity (FMR) | 8,435,949 | $763,115,873 | -41.8% | 8/13/2026 |
| Morgan Stanley | 7,314,292 | $623,543,624 | — | 5/27/2026 |
| Morgan Stanley | 6,339,368 | $573,459,576 | -10.2% | 8/13/2026 |
| Morgan Stanley | 7,060,876 | $565,435,098 | -3.5% | 5/15/2026 |
| Millennium Management | 6,502,638 | $554,349,889 | — | 2/17/2026 |
| Goldman Sachs | 5,142,050 | $411,775,393 | 47.0% | 5/15/2026 |
| Goldman Sachs | 4,549,113 | $411,512,754 | -11.5% | 8/14/2026 |